Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES (ABT)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Summary
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 53% by 2019.
  • The group's high margin levels account for strong profits.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 45.72 USD
Weaknesses
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • With an enterprise value anticipated at 4.35 times the sales for the current fiscal year, the company turns out to be overvalued.
  • With an expected P/E ratio at 48.07 and 35.71 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ABBOTT LABORATORIES46.63%97 853
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.97%226 404
PFIZER12.13%216 886
ROCHE HOLDING LTD.0.77%207 116
MERCK AND COMPANY8.51%174 223
AMGEN25.14%133 501
SANOFI8.99%124 704
BAYER18.99%114 930
BRISTOL-MYERS SQUIBB COMPAN..10.23%105 644
NOVO NORDISK A/S25.13%99 069
GLAXOSMITHKLINE-2.46%98 802
ELI LILLY AND COMPANY18.60%96 039
CELGENE CORPORATION4.82%94 923
ASTRAZENECA16.33%85 977
ALLERGAN PLC-10.35%62 943
More Results
Financials ($)
Sales 2017 27 180 M
EBIT 2017 5 820 M
Net income 2017 2 153 M
Debt 2017 20 403 M
Yield 2017 1,90%
P/E ratio 2017 48,07
P/E ratio 2018 35,71
EV / Sales 2017 4,35x
EV / Sales 2018 3,84x
Capitalization 97 853 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ABBOTT LABORATORIES
Duration : Period : Day
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Duration : Period : Week
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders